DOCSLIB.ORG

Bildiri Kitabi Xxii

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bildiri Kitabi Xxii 1994 BİLDİRİ KİTABI XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu İÇİNDEKİLER Önsöz .............................................................................................................................................................. 2 Kurullar ............................................................................................................................................................ 3 Bilimsel Program .................................................................................................................................. 4 - 14 Konuşmacı Özetleri .......................................................................................................................... 15 - 44 Diyabet Sözlü Bildirileri .................................................................................................................. 45 - 48 Diyabet Poster Bildirileri ................................................................................................................ 49 - 55 Kongre Sözlü Bildirileri ....................................................................................................................56 - 70 Kısa Sözlü Bildiriler ........................................................................................................................... 71 - 76 Kongre Poster Bildirileri ............................................................................................................... 77 - 195 1 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu Değerli Meslektaşlarım, Erciyes Üniversitesi Çocuk Endokrinoloji Bilim Dalımız ve Çocuk Endokrinoloji ve Diyabet Derneği ile ortaklaşa düzenleyeceğimiz XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi için ön çalışma ve hazırlıklarımızı başlatmış bulunuyoruz. Kongre içeriği için bilimsel kurul ilk toplantısını gerçekleştirdi ve konuları belirledi. Kongre öncesi başlayan Diyabet Ekibi Kursu ve Pediatrik Endokrinolojiye Giriş Kursu geleneksel olarak ortak oturumla sonlanacak. Sözel bildiriler ve poster sunumları, ÇEDD-Net çalışmalarının yer alacağı kongremizde, konferans, interaktif oturumlar, karşıt görüşlerin yer alacağı oturumlar düzenlenecektir. Kongrenin yararlı ve verimli geçmesi için en önemli kaynak sizlerin destek ve katılımı olacaktır. Görüşmek dileğiyle, Kongre Düzenleme Kurulu Adına Prof. Dr. Selim Kurtoğlu 2 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu 3 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu XII. DİYABET EKİBİ KURSU – 1. GÜN 18 NİSAN 2018 - ÇARŞAMBA Açılış Konuşmaları Kongre Başkanı 08:30-09:00 Çocuk Diyabet Grubu Başkanı Çocuk ve Adolesan Diyabet Derneği Başkanı Çocuk Endokrinolojisi ve Diyabet Derneği Başkanı A (Temel Düzey) B (İleri Düzey) Oturum Başkanları: Oturum Başkanları: 09:00-10:30 Prof. Dr. Selim Kurtoğlu Prof. Dr. Zehra Aycan Prof. Dr. Dyt. Muazzez Garipağaoğlu Hem. Nurten Variyenli İnsülinler ve Doz Ayarlamaları Yeni İnsülin Anologları Yük. Hem. Nurdan Yıldırım Prof. Dr. Filiz Çizmecioğlu Tip 1 DM Tıbbi Beslenme Tedavisi Süt Çocuğu ve Tip 1 DM Nasıl Uz. Dyt. Volkan Özkaya Tedavi Edelim? Doç. Dr. Şenay Savaş Erdeve Yaş Dönemlerine Göre Diyabetli Çocuk ve Adölesanda Closing the Loop Metabolik Kontrol ve Uzun Süreli İzlem Prof. Dr. İlknur Arslanoğlu Prof. Dr. Nihal Hatipoğlu 10:30-10:45 Kahve Arası Ortak Oturum 1 Oturum Başkanları: 10.45-12.15 Sağlık Çalışanları ve Hastalar için Yeni Diyabet Eğitim Araçları: Prof. Dr. Serap Semiz E-Öğrenme Uz. Dyt. Yasemin Atik Altınok Diyabet Ekibinin Eğitiminde Yeni Yöntemler Prof. Dr. H. İbrahim Durak Aileler ve Olgular İçin Yaşa Uygun Eğitim Modelleri, Öğrenme Hem. Gülcan Delidağ Araçları ve E Eğitim Diyabet Eğitiminde App Uygulamalarının Kullanımı: Değişen Doç. Dr. Tolga Ünüvar Dünyaya Ayak Uydurmak 12:15 - 12:45 Akıllı Işıklar – Contour plus ONE 12:45-13:45 Öğle Yemeği (Poster sunumu) Ortak Oturum 2 Oturum Başkanları: 13:45-15:15 2018 Yılında Dünyada Popülerleşen Beslenme Modelleri ve Doç. Dr. Korcan Demir Tip 1 DM Prof. Dr. Hülya Gökmen Öğün Sıklığının Metabolik Kontrol Üzerine Etkileri Doç. Dr. Alev Keser Düşük Karbonhidrat İçeren Diyetler ve Tip 1 Diyabet Uz. Dyt. Rukiye Bozbulut Mikrobiyata ve Tip 1 DM Prof. Dr. Ener Çağrı Dinleyici 15:15-15:30 Kahve Arası 4 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu XII. DİYABET EKİBİ KURSU – 1. GÜN (Devamı) 15.30-16.00 Diyabet Ekibi Sözel Bildiriler Oturum Başkanları: Prof. Dr. Ruveyde Bundak Hem. Ebru Ercanlı Ağdaş [DS01] Tip 1 Diabetes Mellitus’lu Ergenlerde Sanatla Terapi Tekniklerinin Depresyon, Anksiyete Belirtileri ve Yaşam Kalitesi Üzerine Etkisi:Bir Ön Çalışma Elife Başlı1, Sevgi Özmen2, Esra Demirci2, Mustafa Kendirci3 1Erciyes Üniversitesi Güzel Sanatlar Fakültesi 2Erciyes Üniversitesi Tıp Fakültesi Çocuk Psikiyatrisi BD 3Erciyes Üniversitesi Çocuk Endokrinoloji BD [DS02] Kapsamlı Çocuk Diyabet Programı’nın Metabolik Kontrol Üzerine Etkileri Gizem Bayrakçı1, Tuğba Gökçe1, Serra Küpçüoğlu1, Ekin Deniz Aksu2, Gül Yeşiltepe Mutlu1, Şükrü Hatun1 1Koç Üniversitesi Hastanesi Çocuk Endokrinolojisi ve Diyabet Bölümü 2Koç Üniversitesi Tıp Fakültesi [DS03] Dezavantajlı Diyabetliler Sanıldığından Fazla Mı? Tedaviyi Olumsuz Etkileyebilecek Öznel Durumların Bir Çocuk Diyabet Merkezinde İzlenen Hastalar Arasındaki Sıklığı Gülşen Aytar1, İlknur Arslanoğlu2, Figen Akçalı1 1Düzce Üniversitesi Sağlık Uygulama ve Araştırma Merkezi, Düzce 2Düzce Üniversitesi Tıp Fakültesi, Pediatrik Endokrinoloji Ve Diyabet BD, Düzce [DS04] Süt Çocuğu Diyabet Deneyimlerimiz Elvan Bayramoğlu, Servet Yel, Şenay Savaş Erdeve, Semra Çetinkaya, Melikşah Keskin, Erdal Kurnaz, Nurdan Yıldırım, Zehra Aycan T.C. Sağlık Bilimleri Üniversitesi Dr. Sami Ulus Kadın Doğum, Çocuk Sağlığı ve Hastalıkları Sağlık Uygulama ve Araştırma Hastanesi, Pediatrik Endokrinoloji, Ankara [DS05] Diyabetli Öğrencilerin Akranlarının Diyabet Hakkındaki Bilgilerinin, Tutumlarının ve Diyabet Eğitiminin Sonuçlarının Değerlendirilmesi Hülya Koçyiğit Emek1, Songül Arslan2 1Afyonkarahisar Atatürk Mesleki ve Teknik Anadolu Lisesi 2Afyonkarahisar Kocatepe Üniversitesi Hastanesi Oturum Başkanları: Ortak Oturum 3 16.00-17.30 Prof. Dr. Olcay Evliyaoğlu Tip 1 DM ve Yaşam Psk. Derya Toparlak Diyabetli Bireylerin Engellilik Haklarının İşlevselliği/Merkezi Sistem Sos. Hizm. Uzm. Gülşen Aytar Sınavları-Engellilik Yüzdelerinin İleriki Yaşamlarına Etkileri Tip 1 Diyabetli Olgularda Davranış Değişikliği Nasıl Yaratılabilir Doç. Dr. Şebnem Soysal (Yani Herşeyi Bilen Ama Uygulamayan Çocuğa Nasıl Uygulatılabilinir) Unutulan Tedavi Hedefi: Yaşam Kalitesi Doç. Dr. Çağrı Çövener Oturum Başkanı: 17.30-18.00 Ortak Oturum 5 Prof. Dr. Hülya Günöz Enjeksiyon Teknikleri ve Tedavi Klavuzu Prof. Dr. Şükrü Hatun 20:30-22:30 Kurs Kokteyli 5 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu IV. PEDİATRİK ENDOKRİNOLOJİYE GİRİŞ KURSU – 1. GÜN 18 NİSAN 2018 - ÇARŞAMBA Prof. Dr. Selim Kurtoğlu 08:45-09:00 Kurs Açılışı ve Pediatrik Endokrinolojiye Giriş Prof. Dr. Feyza Darendeliler ÇOCUK ENDOKRİNOLOJİSİNDE GENETİK 09:00-09:30 Endokrinolojide Temel Genetik Kavramlar Doç. Dr. Samim Özen Endokrinolojide Ne Zaman Genetik Test İstenmeli, Hangi 09:30-10:00 Doç. Dr. Samim Özen Sırayla İstenmeli ve Nasıl Yorumlanmalı? BÜYÜME 10:00-10:30 Kısa Boy: Normal mi, Patolojik mi? Prof. Dr. Feyza Darendeliler 10:30-11:00 Büyüme Hormonu Tedavisi: Kime, Ne Zaman, Nasıl? Prof. Dr. Feyza Darendeliler 11:00-11:15 Kahve Arası PUBERTE 11:15-11:45 Normal Puberte: Fizyoloji ve Klinik Prof. Dr. Ayfer Alikaşifoğlu 11:45-12:15 Erken Puberte: Hangisini Durduralım? Prof. Dr. Ayfer Alikaşifoğlu 12:15-12:45 Geç Puberte: Yapısal Gecikme mi, Hipogonadizm mi? Prof. Dr. Gülay Karagüzel 12:45-14:00 Öğle Yemeği ADRENAL VE CİNSİYET GELİŞİM BOZUKLUKLARI 14:00-14:45 46,XX Cinsiyet Gelişim Bozukluklarına Yaklaşım Doç. Dr. Tülay Güran 14:45-15:30 46,XY Cinsiyet Gelişim Bozukluklarına Yaklaşım Prof. Dr. Zehra Aycan 15:30-15:45 Kahve Arası TİROİD 15:45-16:15 Yüksek Neonatal TSH: Nasıl Yönetelim? Prof. Dr. Cengiz Kara 16:15-16.45 Hipotiroidi Prof. Dr. Selim Kurtoğlu 16:45-17:15 Hipertiroidi Prof. Dr. Murat Aydın 20:30-22:30 Kurs Kokteyli 6 XXII. Ulusal Pediatrik Endokrinoloji ve Diyabet Kongresi 18 - 22 Nisan 2018 1994 Cornelia Diamond Otel / Belek - Antalya XVII. Diyabet Ekibi Kursu IV. Pediatrik Endokrinolojiye Giriş Kursu İskeletin Genetik Hastalıkları Kursu İSKELETİN GENETİK HASTALIKLARI KURSU 18 NİSAN 2018 - ÇARŞAMBA 08:15-08:30 Açılış 08:30-09:15 Boy Kısalığına Genel Yaklaşım Prof. Dr. Serap Turan 09:15-10:00 Orantısız Boy Kısalığına Genel Yaklaşım Doç. Dr. Pelin Özlem Şimşek Kiper 10:00-10:15 Kahve Arası
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • February 2021 EPS Pipeline Report
    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
    [Show full text]
  • CHMP Agenda of the 19-22 April 2021 Meeting
    28 July 2021 EMA/CHMP/220334/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 19-22 April 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 19 April 2021, 09:00 – 19:30, virtual meeting/ room 1C 20 April 2021, 08:30 – 19:30, virtual meeting/ room 1C 21 April 2021, 08:30 – 19:30, virtual meeting/ room 1D 22 April 2021, 08:30 – 19:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 8.1.1 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara
    INN-nimet Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency 1.4.
    [Show full text]
  • Networking Breakfast with ASBMR Leaders, NIH Representatives And
    8/20/2019 ASBMR Connect: Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators September 20, 2019, 06:45 AM W308/Orange County Convention Center ASBMR Connect is supported in part by educational grants from Amgen, Inc. and Ultragenyx Pharmaceutical Inc. The Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators is a ticketed event that is part of the ASBMR Connect Program. ASBMR Connect requires advance registration and a separate ticket fee. Registration Open September 20, 2019, 07:00 AM Valencia Ballroom Lobby/Orange County Convention Center Gerald D. Aurbach Lecture and Presentation of Esteemed Awards September 20, 2019, 08:00 AM Valencia Ballroom B-D/Orange County Convention Center Join your colleagues to celebrate the following ASBMR 2019 Esteemed Award Winners: William F. Neuman Award, Paula Stern Achievement Award, Stephen M. Krane Award and Adele L. Boskey Award From Genes to Genomes to Biology and Health • Richard Lifton MD, PhD, Rockefeller University September 20, 08:30 AM-09:30 AM Valencia Ballroom B-D/Orange County Convention Center Networking Break September 20, 2019, 09:30 AM Valencia Foyer/Orange County Convention Center Highlights of the ASBMR 2019 Annual Meeting September 20, 2019, 10:00 AM Valencia Ballroom B-D/Orange County Convention Center • Dana Gaddy PhD, College of Veterinary Medicine, Texas A&M University, United States, Chair • Shonni Silverberg MD, Columbia University College of Physicians & Surgeons, United States, Chair • Johannes Van Leeuwen PhD, Erasmus University Medical Center, Netherlands, Chair This special session is of interest to all health professionals, first time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and/or those seeking guidance in navigating through the extensive ASBMR program.
    [Show full text]
  • PCORI-HCHSS-High Potential Disruption-May-2021
    PCORI Health Care Horizon Scanning System Volume 3 Issue 1 High Potential Disruption Report May 2021 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Jennifer De Lurio, MS Marcus Lynch, PhD, MBA Brian Wilkinson, MA Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, MSPAS, PA-C Misha Mehta, MS Prital Patel, MPH Donna Beales, MLIS Eloise DeHaan, BS Eileen Erinoff, MSLIS Madison Kimball, MS Maria Middleton, MPH Melinda Rossi, BA Kelley Tipton, MPH Rosemary Walker, MLIS Andrew Furman, MD, MMM, FACEP Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
    [Show full text]
  • TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES of INTEREST Please Click This Link for the Cumulative Listing of COVID-19 Resources in Past TAG Mails
    TAG Mail: July to December 2021 Cumulative Listing of Reports, Publications, Medication Safety TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES OF INTEREST Please click this link for the cumulative listing of COVID-19 resources in past TAG Mails. AUSTRALIAN Agency for Clinical Innovation, NSW (ACI) - Caring for adults with COVID-10 in the community. Updated guide to care for adults with Delta variant - link Australian Government Department of Health - ATAGI update following weekly COVID-19 meeting 18 August 2021 - link - PHLN and CDNA joint statement on SARS-CoV-2 rapid antigen tests (updated 23/8/21) - link - Shared decision making guide to COVID-19 vaccination for women who are pregnant, breastfeeding or planning pregnancy - link, factsheets in English and other languages - COVID-19 National Health Plan: Prescriptions via telehealth. Guides for prescribers & pharmacists - ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 (updated 20/8/21) - link MJA Podcasts - Episode 33: COVID-19 in children National COVID-19 Clinical Evidence Taskforce - Taskforce makes new conditional recommendation for sotrovimab - link - New immunodulatory treatments comparison table - link - Tocilizumab and baricitinib FAQs - Ivermectin FAQs NSW Health - COVID-19 vaccination for workers - link - COVID-19 Weekly Surveillance in NSW - Epidemiological week 31, ending 7 August 2021 - link - Safety Notice 018/21: Myocarditis and pericarditis after mRNA COVID-19 vaccines - Statewide Protocol for the Supply or Administration of COVID-19 Vaccine. PD2021_032 (13/08/21) - New ‘find the facts’ webpage which provides data on COVID-19 cases, testing and vaccination and maps showing case numbers and vaccination rates based on location.
    [Show full text]
  • Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: a Review
    International Journal of Molecular Sciences Review Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review Wiktoria Wrobel, Emilia Pach and Iwona Ben-Skowronek * Metabolic Laboratory, Department of Paediatric Endocrinology and Diabetology with Endocrine, Medical University in Lublin, Prof. A. Gebala Street 6, 20-093 Lublin, Poland; [email protected] (W.W.); [email protected] (E.P.) * Correspondence: [email protected]; Tel.: +48-817-185-440 Abstract: Achondroplasia (ACH) is a disease caused by a missense mutation in the FGFR3 (fibroblast growth factor receptor 3) gene, which is the most common cause of short stature in humans. The treatment of ACH is necessary and urgent because untreated achondroplasia has many complications, both orthopedic and neurological, which ultimately lead to disability. This review presents the current and potential pharmacological treatments for achondroplasia, highlighting the advantages and disadvantages of all the drugs that have been demonstrated in human and animal studies in different stages of clinical trials. The article includes the potential impacts of drugs on achondroplasia symptoms other than short stature, including their effects on spinal canal stenosis, the narrowing of the foramen magnum and the proportionality of body structure. Addressing these effects could significantly improve the quality of life of patients, possibly reducing the frequency and necessity of hospitalization and painful surgical procedures, which are currently the only therapeutic options used. The criteria for a good drug for achondroplasia are best met by recombinant human growth hormone at present and will potentially be met by vosoritide in the future, while the rest of the drugs Citation: Wrobel, W.; Pach, E.; are in the early stages of clinical trials.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Ulipristal Acetate
    WHO D rug Information WHO Drug Information provides an overview of topics relating to medicines development, regulation, quality and safety. The journal also publishes and reports on guidance documents and includes lists of International Nonproprietary Names for Pharmaceutical Substances (INN), ATC/DDD classification and monographs for The International Pharmacopoeia. It presents and describes WHO policies and activities while reflecting on technical and pharmaceutical topics of international and regional interest. WHO Drug Information is published four times a year and can be ordered from: WHO Press, World Health Organization, 1211 Geneva 27, Switzerland. e-mail: [email protected] or on line at http://www.who.int/bookorders WHO Drug Information can be viewed at: https://www.who.int/our-work/access-to-medicines-and-health-products/who-drug-information WHO Drug Information, Vol. 35, No. 2, 2021 ISBN 978-92-4-003205-7 (electronic version) ISBN 978-92-4-003206-4 (print version) ISSN 1010-9609 © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC- SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
    OCTOBER 2019 MRx Pipeline A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Michelle Booth, PharmD Director, Medical Pharmacy Strategy Becky Borgert, PharmD, BCOP Pipeline Drug List Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Drug Information Pharmacist Glossary Robert Greer, RPh, BCOP Senior Director, Clinical Strategy and Programs Sam Leo, PharmD Director, Clinical Strategy and Innovation, Specialty Troy Phelps Senior Director, COAR - Analytics Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Magellan Rx Management. 1 | magellanrx.com INTRODUCTION Welcome to the MRx Pipeline. In its third year of publication, this quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report.
    [Show full text]